Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals, Inc. Announces Issuance of Notice of Allowance for Drug Discovery Using First Cart-Activated Receptor
Arena Pharmaceuticals, Inc. Announces Issuance of Notice of Allowance for Drug Discovery Using First Cart-Activated Receptor SAN DIEGO, Nov. 29 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the issuance of a Notice of Allowance ("Allowance") from the United States
View HTML
Toggle Summary Arena Pharmaceuticals Announces 2000 Third Quarter Results; Sequential Quarterly Revenue Growth of 79%
Arena Pharmaceuticals Announces 2000 Third Quarter Results; Sequential Quarterly Revenue Growth of 79% SAN DIEGO, Oct. 25 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA - news ) today reported results for the quarter ended September 30, 2000.
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Achievement Of CART Milestones With Taisho Pharmaceutical Co., Ltd
Arena Pharmaceuticals, Inc. Announces Achievement Of CART Milestones With Taisho Pharmaceutical Co., Ltd SAN DIEGO, Oct. 23 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its May 29, 2000 research agreement with Taisho Pharmaceutical Co., Ltd.,
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. to Provide Telephone and Internet Access For Third Quarter Earnings Conference Call Wednesday, October 25, Live at 4:30 p.m. Eastern Time
Arena Pharmaceuticals, Inc. to Provide Telephone and Internet Access For Third Quarter Earnings Conference Call Wednesday, October 25, Live at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 12 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will host both a telephone and
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Receipt of First CART Milestone Payments From Eli Lilly and Company
Arena Pharmaceuticals, Inc. Announces Receipt of First CART Milestone Payments From Eli Lilly and Company SAN DIEGO, Sept. 25 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its April 14, 2000 research collaboration and license agreement with Eli
View HTML
Toggle Summary Arena Pharmaceuticals Announces 2000 Second Quarter Results
Arena Pharmaceuticals Announces 2000 Second Quarter Results SAN DIEGO, Sept. 6 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported results for the quarter ended June 30, 2000. During the second quarter 2000, the Company reported revenues of $1.3 million versus no revenues for
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Grant of First U.S. Patent; Method Claims Directed to CART-Discovered Inverse Agonist Compounds
Arena Pharmaceuticals, Inc. Announces Grant of First U.S. Patent; Method Claims Directed to CART-Discovered Inverse Agonist Compounds SAN DIEGO, Aug. 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the issuance of United States Patent Number 6,107,324 entitled
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option
Arena Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option SAN DIEGO, Aug. 10 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the underwriters led by ING Barings LLC, Prudential Securities Incorporated, and SG Cowen Securities Corporation, have exercised
View HTML
Toggle Summary Lexicon Genetics and Arena Pharmaceuticals Target New Receptors for Pharmaceutical Development
-- In vivo Screens Detect Modulators of G-Protein Coupled Receptor Activity
View HTML
Toggle Summary New issues ride investor dreams amid Nasdaq selloff
By Denise Duclaux
View HTML